



### Correction: Targeting Brd4 for cancer therapy: inhibitors and degraders

Cite this: *Med. Chem. Commun.*, 2019, 10, 181


Yingchao Duan,<sup>a</sup> Yuanyuan Guan,<sup>a</sup> Wenping Qin,<sup>a</sup> Xiaoyu Zhai,<sup>a</sup> Bin Yu<sup>\*b</sup> and Hongmin Liu<sup>\*b</sup>

DOI: 10.1039/c9md90001b

Correction for 'Targeting Brd4 for cancer therapy: inhibitors and degraders' by Yingchao Duan et al., *Med. Chem. Commun.*, 2018, 9, 1779–1802.

rs.c.li/medchemcomm

The authors regret that some chemical structures are not correct in their review article entitled 'Targeting Brd4 for cancer therapy: inhibitors and degraders'. The corrected structures for compound 20 in Fig. 4, compounds 26–35 in Fig. 6, compounds 96–98 in Fig. 21 and compounds 102–104 in Fig. 23 are shown below.



The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup> School of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China

<sup>b</sup> Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. E-mail: zzuyubin@hotmail.com, liuhm@zzu.edu.cn

